Investor Presentaiton

VegzelmaⓇ ✓ In Europe, actively participated in the tender based on its price advantage and the synergy with existing oncology products ✓ Launched in April 2023, it has registered with Medicare and is currently in the process of discussion to be listed on the plans The global market size of Bevacizumab 41% 24% Global Bevacizumab Market Size $5.7bn 24% 11% US ■ Europe ■ Japan ROW Note: Market size is as of 2022 Source: IQVIA Europe US Launched in October 2022 Obtained the tender with price and the portfolio advantages - Received orders from Finland, Italy, and Belgium - More participation in a tender of other EU countries Launched in April 2023 - Listed in Medicare which covers 20% of the population - Negotiating with the number of payers to be registered in the list Investor Relations 2023 11 2Q23 Business Results Key Products Appendix

View entire presentation